Ultragenyx Pharmaceutical Inc. (RARE)
| Market Cap | 3.50B |
| Revenue (ttm) | 630.60M |
| Net Income (ttm) | -579.83M |
| Shares Out | 96.30M |
| EPS (ttm) | -5.94 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 1,281,227 |
| Open | 36.62 |
| Previous Close | 36.54 |
| Day's Range | 35.94 - 37.25 |
| 52-Week Range | 25.81 - 50.00 |
| Beta | 0.16 |
| Analysts | Strong Buy |
| Price Target | 85.20 (+134.2%) |
| Earnings Date | Nov 4, 2025 |
About RARE
Ultragenyx Pharmaceutical Inc., a biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of novel products for the treatment of rare and ultra-rare genetic diseases in North America, Latin America, Europe, the Middle East, Africa, and the Asia-Pacific. Its biologic products include Crysvita (burosumab), an antibody targeting fibroblast growth factor 23 for the treatment of X-linked hypophosphatemia, as well as tumor-induced osteomalacia; Mepsevii, an enzyme replacement therapy for the treatment... [Read more]
Financial Performance
In 2024, Ultragenyx Pharmaceutical's revenue was $560.23 million, an increase of 29.01% compared to the previous year's $434.25 million. Losses were -$569.18 million, -6.17% less than in 2023.
Financial StatementsAnalyst Forecast
According to 15 analysts, the average rating for RARE stock is "Strong Buy." The 12-month stock price target is $85.2, which is an increase of 134.20% from the latest price.
News
Ultragenyx Pharmaceutical Inc. (RARE) Presents at Evercore 8th Annual Healthcare Conference Transcript
Ultragenyx Pharmaceutical Inc. (RARE) Presents at Evercore 8th Annual Healthcare Conference Transcript
Ultragenyx Pharmaceutical Inc. (RARE) Presents at Citi Annual Global Healthcare Conference 2025 Transcript
Ultragenyx Pharmaceutical Inc. (RARE) Presents at Citi Annual Global Healthcare Conference 2025 Transcript
Ultragenyx Pharmaceutical Inc. (RARE) Q3 2025 Earnings Call Transcript
Ultragenyx Pharmaceutical Inc. ( RARE) Q3 2025 Earnings Call November 4, 2025 5:00 PM EST Company Participants Joshua Higa - Director of Investor Relations & Corporate Communications Emil Kakkis - Fo...
Ultragenyx Announces Sale of a Portion of Future North American Royalties on Crysvita® (burosumab) for $400 Million to OMERS Life Sciences
Bolsters balance sheet with non-dilutive capital at an attractive cost Beginning in January 2028 OMERS will receive an additional 25% of the North American Crysvita® royalty interest capped at 1.55 ti...
Ultragenyx to Host Conference Call for Third Quarter 2025 Financial Results and Corporate Update
NOVATO, Calif., Oct. 28, 2025 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development and commercialization of novel products for seri...
Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
NOVATO, Calif., Oct. 24, 2025 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development and commercialization of novel therapies for rar...
Ultragenyx Appoints Eric Olson as Chief Business Officer and Executive Vice President
NOVATO, Calif., Sept. 30, 2025 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) today announced the appointment of Eric Olson as chief business officer (CBO) and executive vice presid...
Ultragenyx Pharmaceutical Inc. (RARE) Presents at Bank of America Global Healthcare Conference 2025 Transcript
Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) Bank of America Global Healthcare Conference 2025 September 23, 2025 6:35 AM EDT Company Participants Eric Crombez - Chief Medical Officer & Executive VP ...
Ultragenyx Pharmaceutical Inc. (RARE) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference Transcript
Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) Morgan Stanley 23rd Annual Global Healthcare Conference September 9, 2025 4:05 PM EDT Company Participants Eric Crombez - Chief Medical Officer & Executiv...
Ultragenyx Announces Positive Longer-term Data from Phase 3 Study of DTX401 AAV Gene Therapy for the Treatment of Glycogen Storage Disease Type Ia (GSDIa)
At Week 96 participants experienced even greater reductions in daily cornstarch intake while maintaining low levels of hypoglycemia, improved levels of euglycemia and improved fasting tolerance
Ultragenyx Pharmaceutical Inc. (RARE) Presents At Cantor Global Healthcare Conference 2025 Transcript
Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) Cantor Global Healthcare Conference 2025 September 4, 2025 10:55 AM EDT Company Participants Eric Crombez - Chief Medical Officer & Executive VP Howard Ho...
Ultragenyx to Participate at Investor Conferences in September
NOVATO, Calif., Aug. 29, 2025 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development and commercialization of novel therapies for ser...
Ultragenyx Initiates Rolling Submission of Biologics License Application (BLA) to U.S. FDA for DTX401 AAV Gene Therapy for the Treatment of Glycogen Storage Disease Type Ia (GSDIa)
Company expects to complete BLA submission in the fourth quarter of 2025 Company expects to complete BLA submission in the fourth quarter of 2025
Ultragenyx (RARE) Q2 Revenue Up 13%
Ultragenyx (RARE) Q2 Revenue Up 13%
Ultragenyx Pharmaceutical Inc. (RARE) Q2 2025 Earnings Call Transcript
Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) Q2 2025 Earnings Conference Call August 5, 2025 5:00 PM ET Company Participants Emil D. Kakkis - Founder, President, CEO & Director Eric Crombez - Chief M...
Ultragenyx Reports Second Quarter 2025 Financial Results and Corporate Update
Second quarter total revenue of $166 million, Crysvita® revenue of $120 million and Dojolvi® revenue of $23 million
Ultragenyx to Host Conference Call for Second Quarter 2025 Financial Results and Corporate Update
NOVATO, Calif., July 30, 2025 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development and commercialization of novel products for seri...
Ultragenyx: July Selloff Creates Buying Opportunity Ahead Of UX143 Catalyst
Ultragenyx's 35% July selloff is overblown; both UX143 and UX111 programs remain on track with key catalysts ahead. UX143's Phase 3 trial continues for scientific rigor, not due to failure; pivotal da...
Ultragenyx Represents 'Intriguing Buying Opportunity,' Despite Recent Setbacks
HC Wainwright assumed coverage on Ultragenyx Pharmaceuticals, Inc. RARE on Monday, representing an attractive opportunity at current levels.
RARE Investors Have Opportunity to Join Ultragenyx Pharmaceutical Inc. Fraud Investigation with the Schall Law Firm
LOS ANGELES--(BUSINESS WIRE)---- $RARE--RARE Investors Have Opportunity to Join Ultragenyx Pharmaceutical Inc. Fraud Investigation with the Schall Law Firm.
Ultragenyx Pharmaceutical, Apple And Other Big Stocks Moving Lower In Monday's Pre-Market Session
U.S. stock futures were lower this morning, with the Dow futures falling around 100 points on Monday.
US FDA declines to approve Ultragenyx's gene therapy for rare genetic disorder
The U.S. Food and Drug Administration has declined to approve Ultragenyx Pharmaceutical's experimental gene therapy to treat a rare genetic disorder, the company said on Friday.
Ultragenyx Receives Complete Response Letter from FDA for UX111 AAV Gene Therapy to Treat Sanfilippo Syndrome Type A (MPS IIIA)
Complete Response Letter (CRL) cited specific chemistry, manufacturing and controls (CMC) related observations that are resolvable
Ultragenyx, Mereo Shares Dive As Brittle Bone Disease Drug Misses Early Win
Ultragenyx Pharmaceutical Inc. RARE and Mereo BioPharma Group plc MREO stocks are plunging on Thursday.
Methode Electronics, Ultragenyx Pharmaceutical And Other Big Stocks Moving Lower In Thursday's Pre-Market Session
U.S. stock futures were lower this morning, with the Dow futures falling around 100 points on Thursday.